Impact of Reticular Pseudodrusen on Choriocapillaris Flow Deficits and Choroidal Structure on Optical Coherence Tomography Angiography
Overview
Authors
Affiliations
Purpose: To examine the impact of reticular pseudodrusen (RPD) on choriocapillaris blood flow and choroidal structure in individuals with intermediate age-related macular degeneration (AMD).
Methods: Individuals with bilateral large drusen underwent optical coherence tomography (OCT), color fundus photography, near-infrared reflectance, and fundus autofluorescence imaging to determine the presence of RPD. These participants also underwent swept-source OCT angiography (SS-OCTA) imaging to determine (1) choriocapillaris flow deficit (FD) parameters, including the percentage, mean size, and number of FDs present; and (2) choroidal structural parameters, including mean choroidal thickness and choroidal vascularity index. Differences in these parameters between eyes with and without coexistent RPD were examined with and without adjustment for potential key confounders such as drusen volume from the SS-OCTA scans and age.
Results: This study included 102 eyes from 51 individuals with bilateral large drusen, and the analyses showed that there were no significant differences in the choriocapillaris FD parameters (P ≥ 0.062 for all) and choroidal structural parameters (P ≥ 0.059 for all), with or without adjustment for potential confounders in this cohort. However, the percentage of FDs and the mean FD size were both significantly greater with increasing drusen volume (P ≤ 0.038 for both).
Conclusions: The coexistence of RPD in eyes of individuals with intermediate AMD was not associated with significant impairments in choriocapillaris blood flow and choroidal vascular structural changes, with or without adjustment for key confounders. These findings suggest that macular changes in these vascular parameters may not be associated with the presence of RPD.
A cell culture system for RPE hypoxia, a physiologic stressor relevant to AMD deposit formation.
Curcio C, Goerdt L Eye (Lond). 2024; 39(4):611-612.
PMID: 38871935 PMC: 11885480. DOI: 10.1038/s41433-024-03166-2.
Nam J, Nivison-Smith L, Trinh M Invest Ophthalmol Vis Sci. 2024; 65(2):33.
PMID: 38386332 PMC: 10896234. DOI: 10.1167/iovs.65.2.33.
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration.
Clemens C, Eter N, Alten F Ophthalmologica. 2024; 247(2):73-84.
PMID: 38266500 PMC: 11160428. DOI: 10.1159/000536278.
Optical Coherence Tomography Angiography: A 2023 Focused Update on Age-Related Macular Degeneration.
Tombolini B, Crincoli E, Sacconi R, Battista M, Fantaguzzi F, Servillo A Ophthalmol Ther. 2024; 13(2):449-467.
PMID: 38180632 PMC: 10787708. DOI: 10.1007/s40123-023-00870-2.
Krytkowska E, Olejnik-Wojciechowska J, Grabowicz A, Safranow K, Machalinska A J Clin Med. 2023; 12(24).
PMID: 38137797 PMC: 10744131. DOI: 10.3390/jcm12247728.